AIM IMMUNOTECH INC (AIM)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$0.23-2.61%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AIM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -9.5% |
| Our one-year growth estimate | diamond | 4.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 13.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
AIM — M&A activity — Termination
Dated 2026-09-04
Termination of a Material Definitive Agreement. The information set forth in
Why it matters: Successful debt issuance is key for funding operations and growth plans.
Supportive ifManagement says they finished a debt issuance that is more than $10 million.
Worry ifManagement fails to complete the planned debt issuance or delays it further.
Why it matters: New findings on Ampligen's effects against Ebola may help its market and public health.
Supportive ifNew data shows Ampligen works in early studies against Ebola.
Worry ifNo new findings or negative results from research on Ampligen's Ebola use.
Why it matters: Details on debt issuance can show how AIM is managing its capital needs.
Watch forA press release confirms successful completion of a new debt issuance.
Also watch forA delay or failure in the planned debt issuance is reported.
Why it matters: New M&A deals could signal growth and improve investor confidence in AIM.
Supportive ifAIM has a new deal for an acquisition or merger.
Worry ifNo new M&A announcements or delays in planned deals.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$289 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $1,275 loss on $10,000 · 12.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,212 loss on $10,000 · 92.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: M&A activity can drive growth and improve AIM's market position. Any new deals will be closely watched.
Supportive ifA deal was announced for an acquisition worth more than $10 million.
Worry ifNo new M&A announcements or delays in current negotiations.
Why it matters: Data on clinical benefits from the DURIPANC trial will guide the Phase 3 study design.
Supportive ifThe DURIPANC trial showed good results in Q1 2027.
Worry ifThe DURIPANC trial showed negative or unclear data in Q1 2027.
Why it matters: More capital raises may show financial health and support ongoing projects.
Watch forThere is a new equity or debt financing round for clinical trials.
Also watch forNo new capital raises announced, which may mean funding problems.
Why it matters: Data on overall survival is important. It shows if Ampligen works for pancreatic cancer.
Supportive ifOverall survival data shows a big improvement from past results in Q3 2027.
Worry ifOverall survival data does not show a big improvement from past results in Q3 2027.
Why it matters: Changes in how money is spent can affect AIM's growth and financial health.
Watch forAIM has a new plan for spending money that focuses on growth.
Also watch forAIM keeps the same money spending plan without changes.
Why it matters: Earnings results will show if AIM can recover from the recent earnings miss.
Worry ifEarnings results are much better than last quarter.
Less concerning ifEarnings results show another miss or continued losses.
Why it matters: Progress in clinical trials for Ampligen may affect AIM's growth and investor trust.
Supportive ifManagement shares good news. The Phase 3 trial for Ampligen had successful results.
Worry ifManagement reports delays in clinical trials for Ampligen. Some trials have failed.
Why it matters: Getting government funding could improve AIM's finances and growth.
Supportive ifAIM says it got government money for Ampligen's Ebola work.
Worry ifAIM does not get any government funding for its projects.
Why it matters: Staying compliant is important for AIM to trade and raise money well.
Supportive ifFuture updates will confirm that they meet NYSE American standards.
Worry ifThere was a notice of non-compliance with NYSE American standards.